Event Date/Time: Apr 20, 2005
End Date/Time: Apr 22, 2005
What model best addresses the information being pursued in the preclinical development process? How will access to representative in vivo animal models of disease and of specific pathways improve the preclinical development process and toxicity studies? Selecting appropriate assays that will enable researchers to accurately extrapolate results to humans will give considerable leverage to the projects underway. Successful translation of biomarkers from preclinical to clinical can be enabled through the use of imaging reagents, which provide insight into the activity of a compound within a physiologically complex environment, and provide a measure of predicting success in humans. By integrating information from animals and humans we can better understand function and predict drug activity and performance. The use of biomarkers in late stage drug development will improve the decision making process and success rates.